The Future of Cancer Therapy Is Not New Drugs, It’s Smarter Delivery

Summary

As the oncology landscape evolves, a growing body of evidence suggests that smarter drug delivery, rather than continually developing new molecules, holds the key to transforming patient outcomes.

New-molecule development remains enormously expensive and time-consuming, with median research and development costs approaching US$708 million and averages above US$1.3 billion¹. In contrast, innovative drug delivery systems in cancer therapy can repurpose proven pharmacology into highly targeted platforms that enhance bioavailability, improve tumor selectivity, and minimize systemic toxicity².

This article explores why the future of cancer treatment should prioritize targeted drug delivery technologies, leveraging existing compounds more intelligently, reducing patient burden, and accelerating clinical impact.

Introduction: Rethinking the Innovation Paradigm in Oncology

For decades, innovation in oncology has been defined by the discovery of new drugs. The traditional drug development model, including target identification, lead optimization, and clinical trials, typically spans 10–15 years and carries significant financial risk.

Even successful programs incur median R&D costs of approximately US$708 million¹, with some estimates exceeding US$1 billion per approved therapy. Despite this investment, oncology continues to face:

• Low clinical success rates

• Rising development costs

• Persistent treatment-related toxicity

This raises a critical question:

Is the future of cancer therapy really about new drugs, or better delivery of existing ones?

The High Cost and Diminishing Returns of New Cancer Drugs

The economics of oncology drug development are increasingly challenging. A 2025 RAND analysis of 38 FDA-approved drugs found:

• Median R&D cost: US$708 million

• Mean R&D cost: US$1.3 billion¹

At the same time, only ~10% of oncology drugs entering Phase I trials achieve approval.

This combination of high cost and low success rate creates significant inefficiencies. Moreover, many therapies that do reach the market offer only incremental benefits while introducing substantial toxicity.

As healthcare systems and payers demand greater value, the traditional “new molecule” model is becoming increasingly unsustainable.

Why Smarter Drug Delivery Matters in Cancer Treatment

Drug delivery systems in oncology address a fundamental limitation: how to deliver therapeutic agents directly to the tumor while minimizing systemic exposure.

Innovative delivery technologies can:

• Improve drug solubility and stability

• Enhance bioavailability

• Optimize biodistribution

• Increase tumor-specific targeting³

Nanocarriers and advanced delivery platforms enable drugs to bypass first-pass metabolism and achieve higher local concentrations at the tumor site, reducing damage to healthy tissues.

This results in:

• Higher therapeutic index

• Reduced systemic toxicity

• Improved patient tolerability

Real-World Examples of Targeted Drug Delivery

Several FDA-approved therapies demonstrate the power of precision drug delivery:

• Doxil (liposomal doxorubicin) improves pharmacokinetics and reduces cardiotoxicity²

• Abraxane (nab-paclitaxel) enhances tumor delivery and improves response rates³

• CPX-351 improves survival in high-risk acute myeloid leukemia through optimized delivery³

These therapies do not rely on new molecular discovery. Instead, they demonstrate how repurposing existing drugs with advanced delivery systems can lead to superior clinical outcomes.

Beyond Oncology: Broader Impact of Drug Delivery Innovation

Targeted delivery platforms are also transforming other therapeutic areas.

• Ligand-functionalized nanoparticles enable active targeting of tumor-specific receptors, improving drug accumulation²

• Advanced biomaterials allow controlled and sustained drug release, improving adherence and outcomes⁴

These innovations reinforce a key principle:

Therapeutic success is often determined by how a drug is delivered, not just the drug itself.

Challenges and Limitations of Targeted Drug Delivery

Despite its promise, targeted drug delivery faces several challenges.

Many nanoparticle-based systems rely on the enhanced permeability and retention (EPR) effect, where leaky tumor vasculature allows drug accumulation. However, evidence shows that:

• Less than 1% of systemically administered nanoparticles reach solid tumors³

This is due to:

• Biological clearance mechanisms

• Tumor heterogeneity

• Physiological barriers

Active targeting approaches also face limitations, including manufacturing complexity and regulatory hurdles³. These challenges explain why relatively few nanomedicines have reached clinical practice.

A More Efficient Model: Repurposing Drugs Through Precision Delivery

Given the limitations of traditional drug development, drug repurposing combined with advanced delivery technologies offers a more efficient path forward.

This approach enables:

• Faster development timelines

• Reduced clinical risk

• Lower capital requirements

At Onconox, this strategy is central. Our platform focuses on localized drug delivery, including:

• Inhaled therapies for lung cancer

• Intranasal delivery for CNS targeting

These approaches allow:

• Direct delivery to the tumor site

• Reduced systemic exposure

• Improved therapeutic outcomes

Localized delivery bypasses many of the biological barriers associated with systemic administration and aligns with emerging evidence that site-specific delivery improves both efficacy and safety³.

Implications for the Future of Oncology

The shift toward smarter drug delivery has significant implications across the healthcare ecosystem.

For Investors

• Lower development risk

• Faster time to value

• Scalable platform opportunities

For Clinicians

• Improved treatment tolerability

• Better adherence

• Enhanced combination therapy potential

For Patients

• Reduced side effects

• Improved quality of life

• More accessible treatment options

  
  

Conclusion: The Future of Cancer Therapy Is Precision Delivery

The future of cancer therapy is not defined solely by new drugs, but by how effectively we deliver them.

Targeted drug delivery systems have already demonstrated:

• Improved survival outcomes

• Reduced toxicity

• Enhanced tumor selectivity³

Advances in nanotechnology, biomaterials, and localized delivery are overcoming long-standing challenges such as the blood–brain barrier and tumor heterogeneity⁴.

By focusing on smarter delivery of proven molecules, the oncology industry can:

• Accelerate innovation

• Reduce costs

• Improve patient outcomes

At Onconox, we are committed to leading this shift—developing precision delivery platforms that unlock the full potential of existing therapeutics and redefine the future of cancer care.

References

1. Mulcahy AW, Rennane S, Schwam D, et al. Typical cost of developing a new drug is skewed by few high-cost outliers. RAND Corporation. Press release; January 7, 2025.

2. Parvin N, Aslam M, Alam MN, Mandal TK. Nanotechnology driven innovations in modern pharmaceutics: therapeutics, imaging, and regeneration. Nanomaterials. 2025;15(22):1733.

3. Rosenblum D, Joshi N, Tao W, et al. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun. 2018;9(1):1410.

4. Pulsus Group. Drug delivery system: the modern approach to improve therapeutic efficacy. J Basic Clin Pharm. 2024;15(3):353.

By Geoff Muckle

CEO, Onconox